Author: Konstantinos Balaskas (United Kingdom)
Co-authors: Nikolas Pontikos, Eddie Korot, Aljazy Jaber, Peter Thomas, Dawn Sim, Pearse Keane
Purpose
A patient-centric approach to modern eye care involves not only bringing care to patients’ homes, but ideally to the palm of their hands. Smartphone-based apps have been developed that allow self-testing of visual function by patients at home. These technologies could contribute to de-centralisation of care for patients with medical retina disease by reducing the number of hospital visits. Potential applications of home vision monitoring include early detection of progression from intermediate to neovascular Age-related Macular Degeneration (nAMD), fellow eye conversion in patients with nAMD in the first eye as well as monitoring of patients receiving anti-vascular endothelial growth factor (anti-VEGF) treatment for nAMD, Diabetic Macular Oedema (DMO) or macular oedema secondary to Retinal Vein Occlusions (RVO). A significant consideration for real-life deployment of home vision monitoring technologies is assessing their uptake and usability by patients and addressing issues around digital exclusion, particularly in an elderly patient population such as patients with nAMD.
Setting/Venue
This service improvement project was conducted in the high volume intravitreal treatment service of Moorfields Eye Hospital, London, UK - a major tertiary care ophthalmology centre. Patients receiving anti-VEGF treatment for nAMD, DMO or RVOs were prescribed a smartphone-based app (Home Vision Monitor, HVM) linked with a web-based data store and associated portal for review of vision testing results by prescribing clinicians. The HVM app has received FDA 510k clearance (myVisionTrack, Vital Art and Scence, Richardson, USA) and uses shape discrimination tasks to detect metamorphopsia in the central degrees of vision as a metric of visual function.
Methods
Consecutive patients attending Moorfields Eye Hospital for planned anti-VEGF treatment between May 2020 and February 2021 were offered the HVM smartphone app and advised to self-test their vision at least twice a week. A unique link is established between each patient and the prescribing clinician through a registration code. Vision test results (HVM scores) are reviewed by the prescribing clinician on the on-line portal. A change in visual function equivalent to 0.2 on the LogMAR scale triggers an alert and notification message to the clinical team. A patient survey was conducted for a sub-set of patients using the HVM app to assess patient experience and perceptions as well as capture patient characteristics that could influence uptake and engagement. Data from the HVM portal (frequency of use), the Electronic Health Record (demographic and clinical data) and the patient surveys were used to inform an analysis of parameters influencing uptake (defined as successful installation and use of the app at least on one occasion) and engagement/compliance (defined as any continuous period of 4 weeks with use of the app more than once per week) for participating patients. Analysis was performed as part of a registered Moorfields Eye Hospital service improvement audit.
Results
418 patients were included in analysis of factors influencing uptake and engagement for home-vision monitoring. Of those, 258 patients were active users and 160 non-active (uptake assessment). Of active patients with adequate length of follow-up to determine engagement, 166 patients fulfilled the definition of compliance and 92 did not. 114 active patients completed the patient survey. Uptake was significantly associated with age (every 5 years of older age reduced uptake by 5%, p=0.031), biological sex (female users 1.4 times higher uptake than male users, p=0.036) and positively associated with visual acuity in the better seeing eye (p=0.014) and number of intravitreal injections (p= 0.039). Engagement/compliance was significantly associated with diagnosis (nAMD patients were more compliant than patients with DMO or RVO, p=0.003) and was positively associated with white British ethnicity (p=0.025) and visual acuity in the better seeing eye (p=0.007). In the group that completed the patient experience survey, engagement was higher in patients who reported English as their first language (p=0.006) and had a borderline association with higher satisfaction with app use (p=0.06).After adjusting for age, biological sex and diagnosis, engagement was associated with patients' level of comfort with digital technologies and visual acuity in the worse seeing eye.
Conlusions
Home vision monitoring with smartphone-based apps has potential meaningful applications for the care of patients with common medical retina disease. The expected benefits from their deployment in real-life clinical practice pertain to early disease detection, personalised re-treatment intervals, reduction of unnecessary hospital visits and patient empowerment for self-care. Before assessing the potential benefits of home vision monitoring, it is crucial to consider the feasibility of wide-spread real-life deployment of such digital tools for self-care. Uptake and usability of self-monitoring technologies are crucial determinants for their meaningful real-life deployment at scale. In this work, we examined the uptake and engagement with home vision monitoring of patients attending a busy injection clinic for treatment of common retinal conditions. This is the first report of real-life deployment of home-vision monitoring at scale in this patient population. A number of demographic, clinical, socioeconomic and patient perception-related factors were shown to affect uptake and compliance of patients with the use of the prescribed smartphone-based app. As healthcare systems increasingly adopt digital models of care, issues such as digital exclusion require careful consideration to ensure equitable access to high quality care for every patient.
Financial Disclosure
Roche provided funding for the service improvement initiative involving the introduction of home-vision monitoring for the care of patients receiving intravitreal injections at Moorfields Eye Hospital, City Road.
Comments
-